S 24795 (CAS 304679-75-2)

S 24795 (CAS 304679-75-2) References

1. Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons.  |  Lopez-Hernandez, G., et al. 2007. Neuropharmacology. 53: 134-44. PMID: 17544457
2. Improvement of contextual memory by S 24795 in aged mice: comparison with memantine.  |  Beracochea, D., et al. 2008. Psychopharmacology (Berl). 196: 555-64. PMID: 18034231
3. The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus.  |  Lagostena, L., et al. 2008. Neuropharmacology. 54: 676-85. PMID: 18187166
4. Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.  |  Marighetto, A., et al. 2008. Psychopharmacology (Berl). 197: 499-508. PMID: 18265960
5. Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795.  |  López-Hernández, GY., et al. 2009. Neuropharmacology. 56: 821-30. PMID: 19705574
6. α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.  |  Toyohara, J. and Hashimoto, K. 2010. Open Med Chem J. 4: 37-56. PMID: 21249164
7. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.  |  Papke, RL., et al. 2011. J Pharmacol Exp Ther. 337: 367-79. PMID: 21285282
8. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease.  |  Parri, HR., et al. 2011. Biochem Pharmacol. 82: 931-42. PMID: 21763291
9. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.  |  Prickaerts, J., et al. 2012. Neuropharmacology. 62: 1099-110. PMID: 22085888
10. Activation of α7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents Aß-mediated inhibition of LTP in the rat hippocampus.  |  Ondrejcak, T., et al. 2012. Eur J Pharmacol. 677: 63-70. PMID: 22200627
11. α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?  |  Hernandez, CM. and Dineley, KT. 2012. Curr Drug Targets. 13: 613-22. PMID: 22300028
12. Use of behavioural and long-term potentiation models in the development of memory-improving drugs.  |  Blokland, A. and Boess, F. 2008. Expert Opin Drug Discov. 3: 1067-80. PMID: 23506180
13. The α7 nAChR selective agonists as drug candidates for Alzheimer's disease.  |  Fan, H., et al. 2015. Adv Exp Med Biol. 827: 353-65. PMID: 25387975
14. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment.  |  Lombardo, S. and Maskos, U. 2015. Neuropharmacology. 96: 255-62. PMID: 25514383
15. Expression of Concern: Wang et al., 'Dissociating β-Amyloid from α7 Nicotinic Acetylcholine Receptor by a Novel Therapeutic Agent, S 24795, Normalizes α7 Nicotinic Acetylcholine and NMDA Receptor Function in Alzheimer's Disease Brain'.  |  . 2022. J Neurosci. 42: 528. PMID: 34921049